Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510035 | 0.92 | P2RX7 (0.73) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL4504565 | 0.91 | P2RX7 (0.62) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL4498495 | 0.90 | P2RX7 (0.67) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL13958685 | 0.88 | P2RX7 (0.71) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL6484060 | 0.88 | P2RX7 (0.61) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL13958649 | 0.86 | P2RX7 (0.71) | P2RX7LMNASMN1; SMN2P2RX3 | |
| Hydrochloric Acid SCHEMBL4497414 | 0.85 | P2RX7 (0.72) | P2RX7LMNASMN1; SMN2P2RX3 | |
| Hydrochloric Acid SCHEMBL4507061 | 0.85 | P2RX7 (0.72) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL4507850 | 0.85 | P2RX7 (0.55) | P2RX7P2RX3 | |
| SCHEMBL4507860 | 0.84 | P2RX7 (0.57) | P2RX7LMNASMN1; SMN2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090524-A1 | Novel adamantane derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 732/4885EPHX2 1766/4885LMNA 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.